| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
HCW Biologics Inc.$4.55
-0.09 (-2.05%)
F 14Pipeline Score Richly Valued Biotech · Clinical
Market Cap
19.46 M
EPS
-9.46
P/E Ratio
-
Value Trade
2.10 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.50 M
R&D Expenses
1.26 M
Operating CF
-1.58 M
Total Assets
27.34 M
Total Liabilities
21.58 M
Equity
5.76 M
D/E Ratio
12,345
160.36 %
Week
641.03 %
1 Month
362.55 %
3 Month
45.07 %
6 Month
-99.04 %
5 Year
-99.04 %
All Time
Cash Data
Cash Position
1.23 M
Monthly Burn
525.00 K
Runway
0.6 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
30.63 K
52 Week Range
0.25 - 8.75
% held by Insiders
13.23 %
% held by Institutions
4.9 %
Enterprise Value
24.81 M
Total Shares
6.73 M
Short %
3.56 %
Float Shares
6.11 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for HCW Biologics Inc.
260Total events
8Upcoming
38Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 8
Event history 252
Jun 25, 2026
▲Quarterly UpdateCorporate
Completed 28 consecutive trading days above $1.00 per share on June 25, 2026
Jun 24, 2026
●Quarterly UpdateCorporate
Filed amendments to Certificate of Incorporation with Delaware Secretary of State on June 24, 2026
Jun 16, 2026
▲Topline ReadoutHCW9302, an IL-2 fusion proteinClinical Data
Positive preliminary human data readout for first two dose cohorts of HCW9302 monotherapy in alopecia areata
alopecia areatasource ↗
Jun 16, 2026
◆Dose Finding UpdateHCW9302, an IL-2 fusion proteinTrial
Dosing initiated in third dose escalation cohort (8 mcg/kg)
alopecia areatasource ↗
Jun 16, 2026
◆Enrollment UpdateHCW9302, an IL-2 fusion proteinTrial
Patient enrollment on track; dosing initiated in third cohort
alopecia areatasource ↗
May 29, 2026
●Quarterly UpdateCorporate
Received decision letter from Nasdaq Hearings Panel on May 29, 2026
May 27, 2026
▲Partnership / LicenseHCW9206Corporate
Exercised option to regain full ex vivo rights to HCW9206 from Wugen
May 27, 2026
▲Partnership / LicenseHCW9201Corporate
Exercised option to regain full ex vivo rights to HCW9201 from Wugen
May 21, 2026
▼Equity OfferingCorporate
Pricing of approximately $4.0 million private placement offering at-the-market under Nasdaq rules
Drug Pipeline Intelligence
F14
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 11%
Micro Cap (rank 812 of 911)
Percentile RankHCW Biologics Inc. has significant pipeline risk (14/100), with $58M risk-adjusted pipeline value, led by HCW9302, an IL-2 fusion protein in Alopecia Areata(AA) (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCW9302, an IL-2 fusion protein Small molecule | Alopecia Areata(AA) | Phase 1 | NCT07049328 | 10% | $58M | RECRUITING | 30 | STALLED | D (22) | Dec 15, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HCW9302 | alopecia areata | Phase 1 | 2026-06-16 | all three participants showed preliminary indications of improvement in Severity of Alopecia Tool (SALT) scores; ≥25% reduction in SALT scores compared to baseline at four and/or nine weeks after dosing Read More | HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata Read More | |
HCW9302 | alopecia areata | Phase 1 | 2026-06-16 | all three participants showed preliminary indications of improvement in Severity of Alopecia Tool (SALT) scores; ≥25% reduction in SALT scores compared to baseline at four and/or nine weeks after dosing Read More | HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata Read More | |
HCW9302 | alopecia areata | Phase 1 | 2026-06-16 | all three participants showed preliminary indications of improvement in Severity of Alopecia Tool (SALT) scores; ≥25% reduction in SALT scores compared to baseline at four and/or nine weeks after dosing Read More | HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HCWB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HCWB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HCWB▼ -5.1%on this news
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
HCW Biologics Inc. has regained compliance with Nasdaq's Bid Price Rule as of June 29, 2026. The Nasdaq Hearings Panel confirmed this compliance, which is subject to monitoring until June 17, 2027. To maintain compliance, the company will execute a reverse stock split at a one-for-six ratio on June 30, 2026.
Read more →HCWB▼ -8%on this news· ran to -32% by day 3shared move
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
HCW Biologics has announced a 1-for-6 reverse stock split effective June 30, 2026, to comply with Nasdaq's Bid Price Rule. The company has successfully traded above the $1.00 threshold for 28 consecutive days as of June 25, 2026. This move is intended to maintain its listing on the Nasdaq Capital Market and will not affect stockholder ownership percentages.
Read more →HCWB▼ -6.6%on this news
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
HCW Biologics announced positive preliminary results from its Phase 1 clinical trial of HCW9302 for alopecia areata. All participants in the second dose cohort showed a significant reduction in Severity of Alopecia Tool scores. The treatment was well tolerated, with no serious adverse effects reported. The company aims to establish the recommended Phase 2 dose by the end of 2026.
Read more →HCWB▼ -26%on this news
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
HCW Biologics has regained full rights to two commercial-ready reagents, HCW9206 and HCW9201, from Wugen Inc. This move positions the company to leverage these compounds in the growing CAR-T immunotherapy market. HCW9206 shows promise in reducing production costs and enhancing therapeutic efficacy, potentially leading to improved patient outcomes in cancer treatments.
Read more →HCWB▲ +6.2%on this news· ran to -20% by day 3shared move
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
HCW Biologics Inc. has priced a private placement of 2,846,975 units at $1.405 each, targeting to raise approximately $4.0 million. The proceeds will be used to advance clinical trials for their immunotherapeutic products including HCW9302 and HCW11-018b. Each unit comprises common stock or pre-funded warrants along with warrants for additional shares. The offering is expected to close around May 21, 2026, contingent on necessary regulatory approvals.
Read more →HCWBHCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
HCW Biologics announced that its investigational drug HCW11-040, a pembrolizumab-based fusion immunotherapeutic, has shown promise in preventing bronchopulmonary dysplasia (BPD) during IND-enabling studies. This rare pediatric disease affects underweight premature infants, causing severe long-term health issues. The company plans to file an IND application to evaluate HCW11-040 in high-risk patients and is encouraged by potential synergies with reauthorized rare pediatric disease programs. The positive results from studies in an animal model indicate a strong possibility for treating this unmet medical need among neonates.
Read more →HCWBHCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
HCW Biologics reported its first quarter 2026 results, highlighting significant revenue growth and ongoing clinical trials for HCW9302 in alopecia areata. The company successfully closed a licensing deal with Trimmune, generating $3.5 million in cash. However, concerns about its financial viability and potential Nasdaq delisting were noted, emphasizing the need for continued funding.
Read more →HCWB▲ +15.6%on this news
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
HCW Biologics announced the adjournment of its Special Meeting of Stockholders due to insufficient quorum. The proposals will be presented again at the Annual Meeting scheduled for June 15, 2026. The company is encouraging stockholders to vote on proposals related to warrants issued to Armistice Capital, which has invested $17.4 million in HCW Biologics.
Read more →HCWB▲ +16.9%on this newsshared move
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
HCW Biologics has announced significant advancements in its T-Cell Engager Program, specifically with its lead candidate HCW11-018b, which demonstrates strong anti-pancreatic cancer properties. The drug's mechanism of action was unveiled at the AACR Annual Meeting 2026, highlighting its ability to activate within the tumor microenvironment. An IND application is anticipated in the first half of 2027 for clinical trials.
Read more →HCWB▼ -16.7%on this news
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
HCW Biologics reported its fourth quarter and fiscal year 2025 results, highlighting the initiation of a first-in-human clinical trial for HCW9302, aimed at treating alopecia areata. The company received a significant upfront licensing fee for HCW11-006 and launched commercial-ready molecules. However, it faces financial challenges, including doubts about its ongoing viability and decreased revenues.
Read more →HCWB▼ -6.3%on this news· ran to -21% by day 3
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
HCW Biologics has finalized a $7 million exclusive license agreement for HCW11-006 with Beijing Trimmune Biotech. The deal includes a cash payment and equity interest, with Trimmune set to initiate a Phase 1 clinical trial in China in 2027. HCW Biologics retains the option to reclaim rights for the Americas post-trial.
Read more →HCWB▲ +81.2%on this newsshared move
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
HCW Biologics announced positive results for its proprietary compound HCW9206, which enhances the manufacturing of CAR-T cells for treating cancer and infectious diseases. Published in Science Advances, the research indicates that CAR-T cells produced with HCW9206 exhibit improved functionality and persistence compared to traditional methods. The findings suggest that employing HCW9206 may lead to more effective and cost-efficient immunotherapies, with potential applications in HIV treatment and leukemia. The study, led by a prominent team at Albert Einstein College of Medicine, highlights the compound's revolutionary approach to CAR-T therapy production.
Read more →HCWBHCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
HCW Biologics has announced that it has regained compliance with all Nasdaq continued listing rules as of February 26, 2026. This compliance allows the company to access public capital markets to further develop its innovative immunotherapies. CEO Dr. Hing C. Wong emphasized the importance of this compliance for advancing treatments for autoimmune diseases and cancer.
Read more →HCWBHCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
HCW Biologics Inc. has announced the pricing of a follow-on offering of 2,477,292 units at $0.6055 per unit, expected to generate approximately $1.5 million in gross proceeds. The funds will be used for preclinical and clinical development, including trials for their lead product HCW9302. The offering is set to close around February 19, 2026, pending customary conditions.
Read more →HCWB▼ -21.2%on this newsshared move
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
HCW Biologics and WY Biotech have announced the successful closing of their first financing round for their joint venture, Trimmune, which will focus on the development of the preclinical molecule HCW11-006. The venture has secured $7 million in funding and aims to initiate a Phase 1 clinical study in China by the first half of 2027. HCW Biologics retains rights to reclaim the Americas territory, enhancing its strategic position.
Read more →HCWB▼ -17%on this news
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
HCW Biologics has entered a warrant inducement agreement with an investor, allowing the immediate exercise of earlier issued warrants. This agreement will generate approximately $4 million in gross proceeds aimed at supporting the company's ongoing development of immunotherapies for diseases related to chronic inflammation. The investor has agreed to a reduced exercise price for these warrants, and additional new warrants will also be issued in the agreement. The transaction is expected to close around November 20, 2025, pending standard conditions.
Read more →HCWB▼ -21.2%on this news· ran to -35% by day 1shared move
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active co
HCW Biologics has initiated a first-in-human clinical trial for its lead candidate HCW9302, aimed at treating alopecia areata, a poorly managed autoimmune disease. The first patient has been dosed at The Ohio State University Wexner Medical Center, marking a significant milestone for the company. HCW9302 is a novel interleukin-2 fusion molecule intended to activate regulatory T cells, potentially reducing inflammation with fewer side effects compared to existing treatments. The company is positioning HCW9302 as a revolutionary option for patients, with plans to explore its efficacy in other autoimmune diseases.
Read more →HCWB▲ +20.5%on this newsshared move
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results Miramar, FL –
HCW Biologics reported its third-quarter 2025 financial results, highlighting a net loss of $4.6 million. The company is moving forward with a Phase 1 clinical study of HCW9302 for autoimmune diseases, with the first patient expected to be dosed in Q4 2025. Additionally, HCW9302 has entered preclinical trials for alopecia areata, a condition impacting millions. Financial challenges persist, with significant losses and ongoing discussions regarding additional funding needed for future operations.
Read more →HCWBHCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer
HCW Biologics presented updated data on its second-generation immune checkpoint inhibitor, HCW11-040, at the SITC2025 meeting. The drug demonstrated equivalent PD-1/PD-L1 blocking activity to pembrolizumab in preclinical studies. The company plans to advance further IND-enabling studies based on these encouraging results.
Read more →HCWB▼ -9%on this news· ran to -22% by day 3shared move
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
HCW Biologics presented promising preclinical data for its TRBC-based T-Cell Engager program at the SITC 40th Annual Meeting. The lead candidate, HCW11-018b, demonstrated a 100% survival rate in tumor-bearing mice and showed potential for treating various solid tumors, including pancreatic cancer and glioblastoma. The company aims to expand treatment indications beyond cancer.
Read more →HCWBHCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
HCW Biologics Inc. recently participated in a Virtual Investor segment featuring its lead product candidate, HCW11-040, a second-generation immune checkpoint inhibitor. The presentation highlighted the compound's unique formulation and its potential to enhance T cell responses without side effects. The company will also present extensive data on HCW11-040 at the upcoming SITC meeting on November 8, 2025.
Read more →HCWB▼ -7.4%on this news
HCW Biologics to Participate in the 2025 Maxim Growth Summit
HCW Biologics Inc. will participate in the 2025 Maxim Growth Summit on October 22-23 in NYC. CEO Dr. Hing C. Wong will engage with institutional investors and analysts. The event will feature discussions on various sectors, including biotechnology. HCW Biologics focuses on developing immunotherapies to combat diseases linked to chronic inflammation.
Read more →HCWB▼ -7.4%on this newsshared move
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
HCW Biologics Inc. will present three posters at the 40th Annual Meeting of the Society for Immunotherapy of Cancer from November 5 to 9, 2025. The presentations will highlight the results of IND enabling studies of the company's lead drug candidates utilizing its proprietary TRBC platform technology. This platform supports the development of various immunotherapeutic compounds aimed at treating diseases linked to chronic inflammation.
Read more →HCWBHCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
HCW Biologics Inc. participated in a Virtual Investor segment discussing its second-generation T-Cell Engager program. Dr. Peter Rhode highlighted improvements in manufacturability and safety, along with the program's potential to treat various solid tumors. The company aims to address challenges faced by first-generation T-Cell Engagers, enhancing efficacy and tolerability.
Read more →HCWB▲ +5.3%on this news
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
HCW Biologics congratulates Wugen on successfully closing a $115 million equity financing led by Fidelity Management & Research Company. The financing attracted participation from various prominent life sciences investors. HCW Biologics, which holds a minority equity interest in Wugen, recognizes the potential of Wugen's next-generation CAR-T cell therapies.
Read more →HCWB▼ -15.3%on this newsshared move
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
HCW Biologics has designated its TRBC-based immune checkpoint inhibitor, HCW11-040, as its lead candidate for clinical development in treating solid tumors. The drug combines pembrolizumab with cytokines IL-7, IL-15, and TGF-β traps, showing superior preclinical results compared to pembrolizumab alone. The company plans to advance HCW11-040 into late IND-enabling studies.
Read more →HCWB▼ -6.8%on this news· ran to +47% by day 3
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
HCW Biologics has reported positive results from a non-human primate study for its second-generation T-cell engagers, demonstrating safety at higher dose levels. The program aims to tackle challenges faced by first-generation T-cell engagers, particularly in treating solid tumors like pancreatic cancer and glioblastoma. The company is optimistic about forming partnerships to advance its promising therapies.
Read more →HCWB▲ +60.8%on this news
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
HCW Biologics has developed a second-generation immune checkpoint inhibitor based on pembrolizumab, showing promise in treating solid tumors like pancreatic and ovarian cancer. The company will present its findings at Nova Southeastern University on September 12, 2025. The new therapy aims to enhance immune cell activation and infiltration into tumors, potentially improving patient outcomes.
Read more →HCWBHCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results Correction Miramar, FL –
HCW Biologics reported its second-quarter 2025 financial results and business highlights, including a successful $5 million equity offering to support clinical trials. The company plans to initiate a Phase 1 trial for HCW9302, aimed at treating alopecia areata. Despite some positive developments, significant doubts regarding the company’s long-term financial viability were expressed, particularly concerning the reliance on additional funding and the impact of a suspended licensing agreement with Wugen. The company also noted an increase in general and administrative expenses compared to the previous year.
Read more →HCWBHCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results Miramar, FL –
HCW Biologics reported its second quarter 2025 business highlights and financial results, noting a successful $5.0 million equity offering to support its clinical trials. The company has regained compliance with Nasdaq listing requirements and is set to initiate a Phase 1 clinical trial for HCW9302 in the third quarter. However, a one-year suspension of the Wugen License Agreement has raised concerns about future revenues, and significant doubt exists regarding the company's sustainability without further funding.
Read more →HCWB▲ +6.6%on this news
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
HCW Biologics announced the success of its multi-specific T-cell engagers targeting pancreatic cancer, developed using its TRBC technology. These engagers showed promising anti-pancreatic cancer activity in preclinical models, achieving 100% survival in treated tumor-bearing mice. The results will be presented by CEO Dr. Hing C. Wong at the Phoenix Best Science Series on June 27, 2025. The company aims to leverage this technology to potentially treat various solid tumors and improve patient outcomes.
Read more →HCWB▼ -5.2%on this news· ran to -16% by day 3shared move
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements Company in full compliance for continued listing  Miramar, FL –
HCW Biologics Inc. has announced that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement, allowing for its continued listing. Notification from Nasdaq confirming compliance was received on June 24, 2025, after prior compliance with additional listing requirements was achieved. This development indicates that HCWB now fully meets all necessary conditions mandated by Nasdaq, marking a significant milestone for the clinical-stage biopharmaceutical company as it progresses in developing immunotherapies targeting chronic inflammation.
Read more →HCWBHCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
HCW Biologics Inc. has announced the pricing of a $5 million follow-on offering under NASDAQ rules, consisting of 671,140 units priced at $7.45 each. The proceeds are intended for the development of various clinical trials, including their lead candidate HCW9302, and for expanding their research and patent portfolio. The offering is set to close around May 15, 2025, contingent on customary closing conditions. The company also negotiated a reduction in the exercise price of existing warrants to align with this offering.
Read more →HCWB▼ -8.4%on this newsshared move
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025
HCW Biologics has finalized a licensing agreement with WY Biotech, resulting in an upfront payment of $7 million, which will be recognized in Q2 2025. The agreement solidifies the development and commercialization of HCW11-006 for in vivo therapeutic applications. HCW Biologics is also set to receive milestone payments and royalties on future sales, enhancing their financial outlook. This collaboration marks a significant step in advancing HCW Biologics' novel immunotherapy pipeline.
Read more →HCWB▼ -6.9%on this news
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results Miramar, FL –
HCW Biologics has reported its first-quarter 2025 financial results, highlighting a successful $5.0 million equity offering aimed at funding clinical trials. The company is advancing its commercialization efforts for HCW9206 and plans to initiate a Phase 1 trial for HCW9302 in patients with alopecia areata. Despite these advancements, the company faces a net loss and has expressed concerns about its financial sustainability without further funding. G&A expenses have also seen a notable increase, primarily due to past bonus waivers.
Read more →HCWB▲ +92.9%on this newsshared move
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
HCW Biologics announced the successful presentation of its proprietary compound HCW9206 at the 2025 Annual Meeting of American Association of Immunologists. The compound shows potential to improve CAR-T therapies by providing superior efficacy and reducing manufacturing costs. Importantly, HCW9206 enhances the persistence and function of CAR-T cells, which could lead to better treatment outcomes for patients. The company is seeking commercial partnerships to advance HCW9206 for wider use in CAR-T production.
Read more →HCWBHCW Biologics Announces 1-for-40 Reverse Stock Split Miramar, FL –
HCW Biologics has announced a 1-for-40 reverse stock split of its common stock, which will take effect on April 11, 2025. This move aims to comply with Nasdaq's minimum share price requirement of $1.00. Following the split, the number of outstanding shares will decrease significantly while maintaining the total authorized shares at 250 million. The adjustment will not affect stockholders' ownership percentages, though it may impact those holding fractional shares.
Read more →HCWBHCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results Miramar, FL –
HCW Biologics Inc. announced its financial results and business highlights for the fourth quarter and fiscal year 2024. The company received clearance to initiate clinical trials for its drug candidate HCW9302 targeting alopecia areata and has developed a novel drug discovery platform with proprietary compounds. However, HCW Biologics faced a decline in revenues and compliance challenges with Nasdaq listing rules. Despite these challenges, the CEO expressed optimism about their clinical pipeline and business development opportunities.
Read more →HCWBHCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements Miramar, FL –
HCW Biologics Inc. has been granted an extension by the Nasdaq Hearings Panel to regain compliance with its continued listing requirements. Following a hearing, the panel accepted the company's compliance plan, allowing the company to continue its listing provided it meets certain criteria by April 25 and June 15, 2025. The CEO expressed optimism about executing the compliance plan and advancing their immunotherapy development for various diseases. The company is focused on addressing chronic inflammation related to age-related diseases.
Read more →HCWB▲ +128.6%on this news
HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In- Human Phase 1 Clinical Trial This study will evaluate HCW9302 in patients with moderate to severe alopecia areat
HCW Biologics has received FDA clearance to initiate a first-in-human Phase 1 clinical trial for HCW9302, aimed at treating moderate to severe alopecia areata. This trial is significant as alopecia areata currently has no FDA-approved curative treatments and significantly affects patients' quality of life. HCW9302 is an injectable interleukin-2 fusion protein that activates regulatory T cells to manage immune responses. The company's founder emphasized the potential of this trial to develop a transformative treatment for autoimmune conditions.
Read more →HCWBHCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
Dr. Hing C. Wong, Founder and CEO of HCW Biologics, will speak on biomanufacturing challenges and opportunities for cell and gene therapies at the GenScript Biotech Global Forum, coinciding with the J.P. Morgan Healthcare Conference on January 15, 2025. He will discuss how proprietary molecules developed by HCW Biologics may help reduce CGT manufacturing costs and improve efficacy. The conference aims to address key issues in the field, attracting various stakeholders including scientists and regulatory representatives.
Read more →HCWB▼ -11.2%on this news
HCW Biologics Inc. Received NASDAQ Staff Determination Letter Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manne
HCW Biologics Inc. has received a NASDAQ Staff Determination Letter indicating a failure to regain compliance with listing requirements due to its market value dropping below $50 million. The company has until December 16, 2024, to meet the criteria and plans to request a hearing with the Nasdaq Hearing Panel, which could potentially grant an extension of up to 180 days. However, there are no guarantees that the panel will approve the request for continued listing. The firm focuses on developing innovative immunotherapies for various diseases.
Read more →HCWB▲ +320.9%on this news
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
HCW Biologics Inc. has announced the successful pricing of a $6.9 million registered direct offering and concurrent private placement. The offering includes 6,717,000 shares of common stock priced at $1.03 each, above the market price. The deal is expected to close by November 20, 2024, subject to customary conditions. The funds raised will be used to further the company's development of immunotherapies aimed at age-related diseases.
Read more →HCWB▲ +320.9%on this news
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics Inc. has announced a license agreement with WY Biotech to develop a proprietary preclinical immunotherapeutic product candidate. Under the terms of the agreement, HCWB will receive an upfront payment of $7 million, along with opportunities for milestone payments and royalties on future sales. The deal allows HCWB to regain commercialization rights in select territories after Phase 1 trials. Both companies will collaborate on the clinical and commercial development of the candidate, which has demonstrated significant anti-tumor activity in preclinical studies.
Read more →HCWBHCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights Miramar, FL –
HCW Biologics reported its third quarter financial results and business highlights for 2024. The company has expanded its product portfolio and filed an IND application for its immunotherapeutic agent HCW9302. However, it also faces challenges including increased net losses, substantial legal fees from recent arbitration, and uncertainty regarding its financial future. HCW Biologics is engaged in a multi-faceted financing plan to raise necessary capital and comply with Nasdaq listing requirements.
Read more →HCWB▲ +11.6%on this news
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
HCW Biologics reported its financial results for Q2 2024, noting a significant net loss of $15.3 million. The company announced a successful settlement agreement to resolve lengthy arbitration issues, allowing them to progress with their operations. In addition to launching a new multi-faceted financing plan, HCW Biologics is focused on further developing its TOBI platform and preparing for clinical evaluations of HCW9302. However, the company is facing rising legal expenses and concerns about its financial sustainability.
Read more →HCWBHCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights Correction This release has made a correction to a release issued under the same headline on
HCW Biologics reported its second quarter 2024 financial results and highlighted key business developments. The company successfully reached a settlement to resolve a prolonged arbitration, which had hindered its progress. In addition, it announced a new financing strategy, including equity offerings and out-licensing efforts, to support its TOBITM platform and immunotherapy projects. However, the company also faced significant financial losses and rising legal expenses, raising concerns about its future viability without additional funding.
Read more →HCWBHCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights Miramar, FL –
HCW Biologics reported its financial results and business highlights for the first quarter of 2024, emphasizing completed enrollment in clinical trials for its drug HCW9218 targeting solid tumors. The company raised $6.1 million to support its operations but noted substantial doubts about its ability to continue as a going concern without further funding. While the company looks to expand its drug development into age-related conditions, it faced an increase in administrative costs and a rising net loss compared to the previous year, raising concerns over ongoing legal issues related to the Altor/NantCell arbitration.
Read more →HCWBHCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights Miramar, FL –
HCW Biologics reported its fourth-quarter financial results and business highlights for fiscal year 2023. The company achieved significant milestones with the completion of Phase 1 clinical studies for its lead product, HCW9218, targeting solid tumors and pancreatic cancer. Despite these advancements, HCW Biologics faced increased net losses and significant concerns regarding its financial viability moving forward. The company intends to initiate several Phase 2 studies and explore HCW9218's potential for treating age-related diseases, while also managing escalating legal costs and other financial challenges.
Read more →HCWBHCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights Miramar, FL –
HCW Biologics reported its third quarter 2023 financial results, revealing a decrease in revenue compared to the previous year. The company presented positive findings from a Phase 1 trial of HCW9218 at the SITC conference and is optimistic about future studies. However, the financial report highlighted increased general and administrative expenses and a growing net loss. Looking forward, HCW plans to submit an IND application for another candidate, HCW9302, by the end of 2023.
Read more →HCWBHCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
HCW Biologics Inc. will participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York from September 11-13, 2023. The company is currently advancing clinical trials for its immunotherapy HCW9218, which targets solid tumors, including ovarian and pancreatic cancers. So far, the trials report no dose-limiting toxicities, and there is optimism surrounding its potential efficacy as a cancer treatment. Additionally, HCW Biologics has secured multiple patents to protect its innovative therapies and processes.
Read more →HCWBHCW Biologics Reports Second Quarter 2023 Financial Results And Recent Business Highlights Miramar, FL –
HCW Biologics reported its second quarter 2023 financial results, showcasing advancements in its lead immunotherapy candidate, HCW9218, which aims to improve outcomes for cancer therapy when combined with immune checkpoint inhibitors. The company has initiated multiple clinical trials for HCW9218 and has not observed any dose-limiting toxicities thus far. Financially, while revenues increased, the company reported a significant net loss that has raised concerns, alongside rising legal expenses due to ongoing litigation. Additionally, HCW Biologics secured a multi-million dollar line of credit to support its operations and future development activities.
Read more →HCWBHCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
HCW Biologics has been granted U.S. Patent No. 11,672,826 for methods of treating age-related disorders using its bifunctional immunotherapy, HCW9218. This patent reinforces its position in treating cancers associated with aging and chronic inflammation. The company is presently conducting two Phase 1 clinical trials to evaluate HCW9218 for advanced solid tumors and pancreatic cancer, with no dose-limiting toxicities reported. The granting of this patent, alongside recent scientific publications, highlights the company’s potential to redefine treatment approaches for age-related diseases.
Read more →HCWBHCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights Miramar, FL –
HCW Biologics reported its first quarter financial results for 2023, highlighting both revenue declines and operational advancements. The company generated $41,883 in revenue for the quarter, down from $3.1 million in the previous year, primarily due to deferred revenues related to previous transactions. However, significant milestones were achieved, including multiple initiated clinical trials and the establishment of a new manufacturing facility. Amidst these developments, the company faces challenges, including increased operational losses and ongoing legal issues related to arbitration with Altor BioScience and NantCell.
Read more →HCWBHCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
HCW Biologics has successfully secured a $26.25 million non-dilutive financing arrangement to support its expansion efforts, specifically for the buildout of a new headquarters and manufacturing facility. This funding, which is structured as a development line of credit, enables the company to redirect previously planned capital for mid-phase clinical trials of its lead product candidates. With this financial boost, HCW aims to advance its immunotherapy programs without entering unfavorable equity markets. The financing significantly strengthens the company’s operational capabilities and enhances its clinical development strategy.
Read more →HCWBHCW Biologics Poster Presentation at AACR Annual Meeting 2023
HCW Biologics announced the presentation of data for its lead product candidate, HCW9218, at the 2023 AACR Annual Meeting. HCW9218 aims to treat solid tumors by simultaneously stimulating immune responses while inhibiting the immunosuppressive effects of TGF-β. The presentation will include findings on the mechanism of action of HCW9218, which is currently being evaluated in two clinical trials. This meeting serves as an important platform to showcase advancements in the company's immunotherapy research.
Read more →HCWBHCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results And Recent Business Highlights Miramar, FL –
HCW Biologics has released its financial results for the fourth quarter and full year of 2022, highlighting the progress of its clinical trials, especially for its lead candidate HCW9218. The company reported a revenue increase to $6.7 million, driven by the sale of licensed molecules, despite experiencing net losses. Encouragingly, significant milestones in their cancer programs and advancements towards Phase 2 clinical trials were outlined. However, ongoing legal costs and a notable rise in operating expenses present potential challenges to the company's financial stability.
Read more →HCWBHCW Biologics Enters CRADA with National Cancer Institute
MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inf
Read more →HCWBHCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical Development for Cancer MIRAMAR, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- HCW Bi
Read more →HCWBHCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL –
HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL November 7, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics ) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
Read more →HCWBHCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL –
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL August 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics ) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
Read more →HCWBU.S. Patent Issued to HCW Biologics for Foundational Platform Technology Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 Miramar, FL –
U.S. Patent Issued to HCW Biologics for Foundational Platform Technology Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 Miramar, FL August 3, 2022 HCW Biologics Inc. (the Company ) NASDAQ: HCWB), a clinical-stage
Read more →HCWBHCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022
MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade infla
Read more →HCWBU of M begins Phase I of first-in-human clinical trial for advanced solid tumor cancers MINNEAPOLIS, MN
U of M begins Phase I of first-in-human clinical trial for advanced solid tumor cancers MINNEAPOLIS, MN - May 19, 2022 - Physicians and scientists at the University of Minnesota have opened a new solid tumor cancer clinical trial and have treated their first patient with HCW9218
Read more →HCWBHCW Biologics Reports First Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL –
HCW Biologics Reports First Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics ) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immu
Read more →HCWBHCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists
Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells Without Using Feeder Cells Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy Cytokine-Based Fusion Proteins to Expand Human Regulatory T Cells That Circumvents Need for Magnetic Beads For
Read more →HCWBHCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer Debut of preclinical data related to age-associated diseases MIRAMAR, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NA
Read more →HCWBHCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021 $56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023 FDA Clearance for Initial
HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021 $56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023 FDA Clearance for Initial Clinical Trials in Two Difficult-to-Treat Cancer Indicat
Read more →HCWBHCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest
MIRAMAR, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grad
Read more →HCWBMasonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics Novel Bifunctional Fusion Protein UM cleared to proceed with c
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics Novel Bifunctional Fusion Protein UM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced so
Read more →HCWBHCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens
MIRAMAR, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and a
Read more →HCWBHCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022
MIRAMAR, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade
Read more →HCWBHCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022
MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and ag
Read more →HCWBHCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year
MIRAMAR, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade
Read more →HCWBHCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights Miramar, FL
HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights Miramar, FL November 12, 2021 (GLOBE NEWSWIRE) HCW Biologics Inc. (the Company or HCW Biologics ) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing n
Read more →HCWBHCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company
HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company s lead product candidate, in refractory, advanced/metasta
Read more →HCWBHCW Biologics Announces Appointment of Two New Members to Board of Directors
MIRAMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade infla
Read more →HCWBHCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform Preclinical Data Demonstrated HCW9218 Antitumor Activity as Single-Agent Monotherapy and as an Adjunct to Enhance Potency of Therapeutic Antibodies Investigational New Drug Application (“IND”) for
Read more →HCWBHCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform
TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells MIRAMAR, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ: HCWB), an innovative biopharmaceutical co
Read more →HCWBHCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights Miramar, FL
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights Miramar, FL August 13, 2021 HCW Biologics Inc. (the Company ) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen he
Read more →HCWB▼ -7.4%on this news
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic,
Read more →HCWBHCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering MIRAMAR, FL /
HCW Biologics Inc. Announces Pricing of $56.0 Million Initial July 19, 2021 / HCW Biologics Inc. (NASDAQ:HCWB) (the Company ), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupt
Read more →Competitive Position
How HCWB ranks across every disease it competes inCompetitive Position is a premium feature
See how HCWB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial